Gender differences in outcomes of patients with cystic fibrosis

Journal of Women's Health

Volumn 23, Issue 12, 2014, Pages 1012-1020

  Harness Brumley, Cayce L ^a   Elliott, Alan C ^b   Rosenbluth, Daniel B ^c   Raghavan, Deepa ^a   Jain, Raksha ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SOUTHERN METHODIST UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACHROMOBACTER XYLOSOXIDANS; ADULT; ARTICLE; ASPERGILLUS; BURKHOLDERIA CEPACIA; COHORT ANALYSIS; CYSTIC FIBROSIS; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA PNEUMONIAE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; OUTCOME ASSESSMENT; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; UNITED STATES; ADOLESCENT; BACTERIUM; CHILD; COMPARATIVE STUDY; COMPLICATION; EVALUATION STUDY; INCIDENCE; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MICROBIOLOGY; MIDDLE AGED; MORTALITY; ONSET AGE; PATHOGENICITY; PROPORTIONAL HAZARDS MODEL; REGISTER; RESPIRATORY TRACT INFECTIONS; SOCIOECONOMICS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; BACTERIA; CHILD; CYSTIC FIBROSIS; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LIFE EXPECTANCY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84918569465     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2014.4985     Document Type: Article

References (44)

1. Marshall BC. Cystic Fibrosis Foundation Patient Registry: 2013. Annual Data Report. Available at http://cff.org Accessed on December 5, 2014.
2. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-642.
3. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
4. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365:1663-1672.
5. Rosenfeld M, Davis R, FitzSimmons S, Pepe MRamsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145:794-803.
6. Taveira-DaSilva AM Moss J. Optimizing treatments for lymphangioleiomyomatosis. Expert Rev Respir Med 2012; 6:267-276.
7. Thenappan T, Shah SJ, Rich SGomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-1110.
8. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry. Chest 2010;137:376-387.
9. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566-572.
10. Hyland RA, Ware S, Johnson ARYates DH. Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia. Scand J Work Environ Health 2007;33:286-292.
11. Wisnivesky JP Halm EA. Sex differences in lung cancer survival: Do tumors behave differently in elderly women? J Clin Oncol 2007;25:1705-1712.
12. Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006;130:1796-1802.
13. Morrissey BM Harper RW. Bronchiectasis: Sex and gender considerations. Clin Chest Med 2004;25:361-372.
14. Farha S, Asosingh K, Laskowski D, et al. Effects of the menstrual cycle on lung function variables in women with asthma. Am J Respir Crit Care Med 2009;180:304-310.
15. Celli B, Vestbo J, Jenkins CR, et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med 2011;183:317-322.
16. Han MK, Postma D, Mannino DM, et al. Gender and chronic obstructive pulmonary disease: Why it matters. Am J Respir Crit Care Med 2007;176:1179-1184.
17. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003;22:470-477.
18. Corey M Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996; 143:1007-1017.
19. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
20. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
21. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-1049.
22. Nick JA, Chacon CS, Brayshaw SJ, et al. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2010;182:614-626.
23. Assael BM, Castellani C, Ocampo MB, et al. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. Am J Epidemiol 2002; 156:397-401.
24. Viviani L, Bossi AAssael BM. Absence of a gender gap in survival. An analysis of the Italian registry for cystic fibrosis in the paediatric age. J Cyst Fibros 2011;10:313-317.
25. Verma N, Bush ABuchdahl R. Is there still a gender gap in cystic fibrosis? Chest 2005;128:2824-2834.
26. Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303:2386-2392.
27. Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697-2708.
28. Fogarty AW, Britton J, Clayton ASmyth AR. Are measures of body habitus associated with mortality in cystic fibrosis? Chest 2012;142:712-717.
29. Chamnan P, Shine BS, Haworth CS, Bilton DAdler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 2010;33:311-316.
30. de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680-685.
31. Chotirmall SH, Smith SG, Gunaratnam C, et al. Effect of estrogen on pseudomonas mucoidy and exacerbations in cystic fibrosis. N Engl J Med 2012;366:1978-1986.
32. Maselli JH, Sontag MK, Norris JM, et al. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol 2003;35:257-262.
33. Mirsaeidi M, Hadid W, Ericsoussi B, Rodgers DSadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. Int J Infect Dis 2013;17:e1000-1004.
34. Tsuyuguchi K, Suzuki K, Matsumoto H, et al. Effect of oestrogen on Mycobacterium avium complex pulmonary infection in mice. Clin Exp Immunol 2001;123:428-434.
35. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: Prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008;178:1066-1074.
36. Sweezey NB, Ghibu FGagnon S. Sex hormones regulate CFTR in developing fetal rat lung epithelial cells. Am J Physiol 1997;272:L844-851.
37. Singh AK, Schultz BD, Katzenellenbogen JA, et al. Estrogen inhibition of cystic fibrosis transmembrane conductance regulator-mediated chloride secretion. J Pharmacol Exp Ther 2000;295:195-204.
38. Coakley RD, Sun H, Clunes LA, et al. 17beta-Estradiol inhibits Ca2 + -dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia. J Clin Invest 2008;118:4025-4035.
39. Jain R, Ray JM, Pan JHBrody SL. Sex hormonedependent regulation of cilia beat frequency in airway epithelium. Am J Respir Cell Mol Biol 2012;46:446-453.
40. Sutton S, Rosenbluth D, Raghavan D, Zheng JJain R. Effects of puberty on cystic fibrosis related pulmonary exacerbations in women versus men. Pediatr Pulmonol 2014;49:28-35.
41. Chotirmall SH, Greene CM, Oglesby IK, et al. 17Betaestradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med 2010;182:62-72.
42. Chotirmall SH, Greene CMMcElvaney NG. Immune, inflammatory and infectious consequences of estrogen inwomen with cystic fibrosis. Expert Rev Respir Med 2012;6:573-575.
43. Wang Y, Cela E, Gagnon SSweezey NB. Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice. Respir Res 2010;11:166.
44. Masterson TL, Wildman BG, Newberry BHOmlor GJ. Impact of age and gender on adherence to infection control guidelines and medical regimens in cystic fibrosis. Pediatr Pulmonol 2011;46:295-301.